Physician profile
Christopher Michael Ward
NPI 1255560009
$823.40
in general payments reported to CMS, 2019-2025
12 companies · $495 in 2025
The $495 reported for 2025 was more than what 97% of Nurse Anesthetist, Certified Registered providers received nationally (typical 2025 total: $45.72).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $89.08 · 2024: $239 · 2025: $495.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $823.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $823.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aimmune Therapeutics, INC. | $160.72 | 2024-2025 | Zenpep, Vowst |
| Ardelyx, INC. | $121.99 | 2024-2025 | Ibsrela |
| Regeneron Healthcare Solutions, INC. | $80.13 | 2025 | Dupixent |
| Madrigal Pharmaceuticals | $78.21 | 2024-2025 | Rezdiffra, Resmetirom |
| Takeda Pharmaceuticals U.S.A., INC. | $71.05 | 2024-2025 | Entyvio, Eohilia |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $65.68 | 2025 | Xifaxan |
| Peerless Surgical INC. | $63.59 | 2023 | |
| Merck Sharp & Dohme LLC | $60.17 | 2023-2024 | Dificid, Delstrigo, Pifeltro |
| Qol Medical, LLC | $51.59 | 2025 | Sucraid |
| Lilly USA, LLC | $28.36 | 2024 | Omvoh |
| Intercept Pharmaceuticals, INC. | $27.69 | 2024 | |
| Phathom Pharmaceuticals, INC. | $14.22 | 2025 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Ward listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.